In-vitro dissolution profile comparison: Statistics and analysis, model dependent approach

被引:104
作者
Sathe, PM
Tsong, Y
Shah, VP
机构
[1] Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD 20855
关键词
dissolution profile comparison; statistics; model dependent analysis;
D O I
10.1023/A:1016020822093
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To develop and propose a 'model dependent' approach for the in-vitro dissolution profiles comparison. Methods. Diltiazem hydrochloride tablet dissolution profiles were compared using a statistical approach based on a mathematical model. A similarity region (SR) was defined based on the intra- and inter-lot parameter variances of the final production size standard lots. Statistical distances between the test and reference lot parameter means were computed and normalized. A 90% confidence region (CR) was developed around the statistical distance. The confidence region was compared with the similarity region to assess the similarity or dis-similarity of the test and reference (REF) lot dissolution profiles. Two test lots, one with a 'minor' modification(mm) the other with a 'major' modification (MM), were evaluated. Results. 'Weibull' was selected as the 'model' function. A comparison of the confidence regions around the statistical distance of 'mm-REF' and 'MM-REF' with the similarity region, suggested that the dissolution profiles of the 'mirror' modification lot were similar and that of 'major' modification lot were dis-similar to the reference lot. Conclusions,. A 'model dependent' approach was shown to be useful for the inter-lot in-vitro dissolution profiles comparison.
引用
收藏
页码:1799 / 1803
页数:5
相关论文
共 8 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]  
JOHNSON RA, 1989, APPLIED MULTIVARIATE
[3]   MODELING S-SHAPED DISSOLUTION CURVES [J].
KERVINEN, L ;
YLIRUUSI, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 92 (1-3) :115-122
[4]  
Moore J.W., 1996, PHARM TECHNOL, V20, P64, DOI DOI 10.1017/CCOL521633230.011
[5]  
MOORE JW, 1994, PHARMACEUT RES, V11, pS171
[6]   BIOEQUIVALENCE [J].
RESCIGNO, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (07) :925-928
[7]  
TSONG Y, 1996, UNPUB DRUG INFORMATI
[8]  
1995, US PHARMACOPEIA, V23, P1791